NeuroSense Therapeutics Ltd - Warrants (09/11/2026)
NRSNW
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.42K
Close$
$-0.00
129.5% downside
Current Fair Value
129.5% downsideOvervalued by 129.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13,419.00 |
|---|---|
| Enterprise Value | $17,419.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.8 |
| Beta | 1.6 |
| Outstanding Shares | 1,278,000 |
Return
| Return on Equity | 713.14% |
|---|---|
| Return on Assets | -1082.20% |
| Return on Invested Capital | 744.96% |
Valuation & Multiples
| P/E Ratio | -0.52 |
|---|---|
| PEG | -0.66 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 9.76 |
| Debt to Equity | -0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 25, 2026
EPS Estimate
$-3.90
Average shareholder expectationRevenue Estimate
$267,800
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-0.79
Average shareholder expectationRevenue Estimate
$535,600
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.65%▼ 0.00% |
|---|---|
| Total Invested | $10,372▼ 68.40% |
| Investors Holding | 30% |
ESG Score
No data